# US 2004/0018529 A1 · Functional cloning of genes encoding proteins/enzymes involved in proteolytic cleavage

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018529 A1
- Document ID: US20040018529A1
- Status: Published application
- Kind: A1
- Application number: 10/447,655
- Filed: 2003-05-28
- Published: 2004-01-29
- Earliest claimed: 1999-10-20
- Inventors: Yonghong Li; Barbara Cordell
- Web page: https://patentgrep.com/patent/US20040018529A1

## CPC

- C12N 9/6472: {Cysteine endopeptidases (3.4.22)}
- C12N 9/6475: {Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}
- C12N 15/1034: {Isolating an individual clone by screening libraries}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This invention concerns methods and means for the functional cloning of genes encoding proteins or enzymes involved in proteolytic cleavage. The invention is based on the use of caspase expression cassettes comprising the coding sequence of a proteolytic cleavage site flanked by sequences encoding two caspase subunits.

## Claims

### Claim 1

A method of identifying inhibitors of a protease comprising:
providing a eukaryotic cell susceptible to caspase-induced apoptosis, wherein the eukaryotic cell expresses a gene encoding a protease, and wherein the protease recognizes a proteolytic cleavage site;
introducing a fusion polypeptide expression vector into the eukaryotic cell, wherein the fusion polypeptide expression vector comprises an expression cassette encoding an inducible promoter that regulates a gene for a fusion polypeptide, wherein the fusion polypeptide comprises an amino acid sequence for a first caspase subunit, a linker sequence, a second caspase subunit, wherein the linker sequence comprises the proteolytic cleavage site;
introducing a cDNA expression vector into the eukaryotic cell, wherein the cDNA expression vector expresses an inhibitor that inhibits the protease from cleaving the proteolytic cleavage site of the fusion polypeptide in the eukaryotic cell;
inducing the expression of said fusion polypeptide;
isolating the eukaryotic cell after induction that contains the cDNA expression vector and survives induction; and
isolating the cDNA expression vector that expresses the inhibitor from the eukaryotic cell that survives induction.

### Claim 2 (depends on 1)

The method of claim 1 wherein said first caspase subunit and second caspase subunit are the small subunit and large subunit subunits of a native human caspase-3 polypeptide.

### Claim 3 (depends on 1)

The method of claim 1 wherein the caspase-induce apoptosis is induced by exogenous caspase-3 expression.

### Claim 4 (depends on 1)

The method of claim 1 wherein said inducible promoter is a tet-operator modified CMV promoter.

### Claim 5 (depends on 1)

The method of claim 1 wherein said protease is β-secretase.

### Claim 6 (depends on 5)

The method of claim 5 wherein said eukaryotic cell is a MCF-7 cell.

### Claim 7 (depends on 1)

The method of claim 1, wherein the gene encoding the protease is a gene exogenous to the eukaryotic cell.

### Claim 8 (depends on 1)

The method of claim 1, wherein the gene encoding the protease is a gene endogenous to the eukaryotic cell.

### Claim 9 (depends on 1)

The method of claim 1, wherein the inhibitor is a caspase inhibitor.

### Claim 10 (depends on 1)

The method of claim 1 wherein said inhibitor is an antisense transcript of said protease.

### Claim 11 (depends on 1)

The method of claim 1 wherein said inhibitor is a trans-dominant derivative of said protease.

### Claim 12 (depends on 1)

The method of claim 1 wherein said inhibitor negatively regulates the activity of said protease.

### Claim 13 (depends on 1)

The method of claim 1 wherein said inhibitor inhibits the expression of said protease.

### Claim 14 (depends on 1)

The method of claim 1 wherein the cDNA expression vector is derived from a cDNA expression library.

### Claim 15 (depends on 14)

The method of claim 14 wherein said library is a retroviral cDNA expression library.
